|
Gene: DLG2 |
Gene summary for DLG2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DLG2 | Gene ID | 1740 |
Gene name | discs large MAGUK scaffold protein 2 | |
Gene Alias | PPP1R58 | |
Cytomap | 11q14.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q15700 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1740 | DLG2 | HTA12-18-3 | Human | Pancreas | PDAC | 4.07e-03 | 5.29e-01 | 0.0716 |
1740 | DLG2 | HTA12-23-1 | Human | Pancreas | PDAC | 2.91e-17 | 1.28e+00 | 0.3405 |
1740 | DLG2 | HTA12-25-1 | Human | Pancreas | PDAC | 3.74e-18 | 1.20e+00 | 0.313 |
1740 | DLG2 | HTA12-26-1 | Human | Pancreas | PDAC | 9.91e-34 | 1.50e+00 | 0.3728 |
1740 | DLG2 | HTA12-29-1 | Human | Pancreas | PDAC | 1.48e-110 | 1.81e+00 | 0.3722 |
1740 | DLG2 | HTA12-30-1 | Human | Pancreas | PDAC | 3.91e-06 | 1.30e+00 | 0.3671 |
1740 | DLG2 | HTA12-32-1 | Human | Pancreas | PDAC | 4.23e-05 | 1.12e+00 | 0.3624 |
1740 | DLG2 | HTA12-9-1 | Human | Pancreas | PDAC | 1.32e-03 | 3.96e-01 | 0.1532 |
1740 | DLG2 | HTA12-9-2 | Human | Pancreas | PDAC | 1.65e-02 | 3.01e-01 | 0.0835 |
1740 | DLG2 | HTA12-9-3 | Human | Pancreas | PDAC | 7.02e-05 | 7.58e-01 | 0.2045 |
1740 | DLG2 | 047563_1562-all-cells | Human | Prostate | BPH | 5.80e-06 | 3.86e-01 | 0.0791 |
1740 | DLG2 | 048752_1579-all-cells | Human | Prostate | BPH | 1.92e-24 | 6.18e-01 | 0.1008 |
1740 | DLG2 | 052095_1628-all-cells | Human | Prostate | BPH | 1.46e-15 | 4.81e-01 | 0.1032 |
1740 | DLG2 | 052097_1595-all-cells | Human | Prostate | BPH | 2.52e-11 | 3.52e-01 | 0.0972 |
1740 | DLG2 | 052099_1652-all-cells | Human | Prostate | BPH | 1.27e-20 | 5.51e-01 | 0.1038 |
1740 | DLG2 | PTC04 | Human | Thyroid | PTC | 1.85e-03 | -2.55e-02 | 0.1927 |
1740 | DLG2 | PTC05 | Human | Thyroid | PTC | 6.30e-03 | 7.59e-02 | 0.2065 |
1740 | DLG2 | PTC06 | Human | Thyroid | PTC | 3.31e-09 | 4.04e-02 | 0.2057 |
1740 | DLG2 | ATC5 | Human | Thyroid | ATC | 3.48e-04 | -4.46e-02 | 0.34 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0009135 | Colorectum | AD | purine nucleoside diphosphate metabolic process | 47/3918 | 103/18723 | 1.61e-08 | 9.22e-07 | 47 |
GO:0009179 | Colorectum | AD | purine ribonucleoside diphosphate metabolic process | 47/3918 | 103/18723 | 1.61e-08 | 9.22e-07 | 47 |
GO:0009185 | Colorectum | AD | ribonucleoside diphosphate metabolic process | 47/3918 | 106/18723 | 4.85e-08 | 2.55e-06 | 47 |
GO:0007163 | Colorectum | AD | establishment or maintenance of cell polarity | 77/3918 | 218/18723 | 5.72e-07 | 2.08e-05 | 77 |
GO:0009132 | Colorectum | AD | nucleoside diphosphate metabolic process | 49/3918 | 124/18723 | 1.75e-06 | 5.31e-05 | 49 |
GO:0045197 | Colorectum | AD | establishment or maintenance of epithelial cell apical/basal polarity | 20/3918 | 44/18723 | 2.26e-04 | 2.94e-03 | 20 |
GO:0010038 | Colorectum | AD | response to metal ion | 106/3918 | 373/18723 | 3.22e-04 | 3.83e-03 | 106 |
GO:0035088 | Colorectum | AD | establishment or maintenance of apical/basal cell polarity | 21/3918 | 49/18723 | 4.31e-04 | 4.82e-03 | 21 |
GO:0061245 | Colorectum | AD | establishment or maintenance of bipolar cell polarity | 21/3918 | 49/18723 | 4.31e-04 | 4.82e-03 | 21 |
GO:0071248 | Colorectum | AD | cellular response to metal ion | 61/3918 | 197/18723 | 5.74e-04 | 6.09e-03 | 61 |
GO:0071241 | Colorectum | AD | cellular response to inorganic substance | 68/3918 | 226/18723 | 6.98e-04 | 7.10e-03 | 68 |
GO:0009126 | Colorectum | AD | purine nucleoside monophosphate metabolic process | 19/3918 | 44/18723 | 7.13e-04 | 7.21e-03 | 19 |
GO:0030705 | Colorectum | AD | cytoskeleton-dependent intracellular transport | 60/3918 | 195/18723 | 7.56e-04 | 7.59e-03 | 60 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa045301 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa045302 | Colorectum | SER | Tight junction | 59/1580 | 169/8465 | 3.24e-07 | 5.98e-06 | 4.34e-06 | 59 |
hsa045303 | Colorectum | SER | Tight junction | 59/1580 | 169/8465 | 3.24e-07 | 5.98e-06 | 4.34e-06 | 59 |
hsa045304 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
hsa04390 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
hsa045305 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
hsa043901 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
hsa0453026 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa043909 | Endometrium | AEH | Hippo signaling pathway | 38/1197 | 157/8465 | 4.79e-04 | 3.38e-03 | 2.47e-03 | 38 |
hsa04530112 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0439014 | Endometrium | AEH | Hippo signaling pathway | 38/1197 | 157/8465 | 4.79e-04 | 3.38e-03 | 2.47e-03 | 38 |
hsa0453027 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0439023 | Endometrium | EEC | Hippo signaling pathway | 39/1237 | 157/8465 | 4.54e-04 | 3.47e-03 | 2.59e-03 | 39 |
hsa0453036 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0439033 | Endometrium | EEC | Hippo signaling pathway | 39/1237 | 157/8465 | 4.54e-04 | 3.47e-03 | 2.59e-03 | 39 |
hsa051656 | Lung | IAC | Human papillomavirus infection | 71/1053 | 331/8465 | 1.88e-06 | 7.63e-05 | 5.06e-05 | 71 |
hsa0453016 | Lung | IAC | Tight junction | 43/1053 | 169/8465 | 2.44e-06 | 8.81e-05 | 5.85e-05 | 43 |
hsa043907 | Lung | IAC | Hippo signaling pathway | 35/1053 | 157/8465 | 3.60e-04 | 3.45e-03 | 2.29e-03 | 35 |
hsa0516511 | Lung | IAC | Human papillomavirus infection | 71/1053 | 331/8465 | 1.88e-06 | 7.63e-05 | 5.06e-05 | 71 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DLG2 | SNV | Missense_Mutation | c.664G>A | p.Asp222Asn | p.D222N | Q15700 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DLG2 | SNV | Missense_Mutation | novel | c.1121C>T | p.Ser374Leu | p.S374L | Q15700 | protein_coding | tolerated(0.06) | probably_damaging(0.995) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DLG2 | insertion | Nonsense_Mutation | novel | c.625-1_625insCCAGCATAGCCAAACCCCATCTCTA | p.Gly209ProfsTer3 | p.G209Pfs*3 | Q15700 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
DLG2 | SNV | Missense_Mutation | novel | c.1898N>T | p.Ser633Phe | p.S633F | Q15700 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DLG2 | SNV | Missense_Mutation | novel | c.98N>C | p.Lys33Thr | p.K33T | Q15700 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.969) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DLG2 | SNV | Missense_Mutation | c.2706A>C | p.Lys902Asn | p.K902N | Q15700 | protein_coding | deleterious(0) | possibly_damaging(0.676) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
DLG2 | SNV | Missense_Mutation | c.106N>A | p.Glu36Lys | p.E36K | Q15700 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.953) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
DLG2 | SNV | Missense_Mutation | rs150043290 | c.365N>A | p.Arg122Gln | p.R122Q | Q15700 | protein_coding | deleterious_low_confidence(0.04) | benign(0.226) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DLG2 | SNV | Missense_Mutation | novel | c.9N>G | p.Ile3Met | p.I3M | Q15700 | protein_coding | deleterious_low_confidence(0) | benign(0.248) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DLG2 | SNV | Missense_Mutation | c.1567G>C | p.Glu523Gln | p.E523Q | Q15700 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-VS-A9UI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |